Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05235269
Other study ID # AT01--001
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date November 30, 2021
Est. completion date December 30, 2022

Study information

Verified date September 2022
Source Attralus, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to assess the repeatability of organ-specific quantitation of radiotracer uptake following Positron Emission Tomography/Computed Tomography (PET/CT) imaging of AT- 01 in subjects with amyloid light chain (AL) or amyloid transthyretin (ATTR) systemic amyloidosis.


Description:

This is a multicenter, open label, single arm study in subjects with amyloid light chain (AL) or amyloid transthyretin (ATTR) systemic amyloidosis with visceral amyloid deposits. This study consists of a screening period of up to 30 days; two one-day treatment periods (Day 1 and Week 6); a safety follow-up 24-48 hours after the second administration of 124I AT-01, and a safety follow-up visit 28 days after the second administration of 124I-AT-01.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 27
Est. completion date December 30, 2022
Est. primary completion date October 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Understands the study procedures and is capable of giving signed informed consent, as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. 2. Male or female =18 years of age. 3. For women of childbearing potential: agreement to remain abstinent or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 90 days after the last dose of 124I-AT-01. 1. A woman is considered of childbearing potential if she is postmenarchal, has not reached a postmenopausal state, and has not undergone surgical sterilization. 2. Examples of contraceptive methods with a failure rate of <1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. 3. Contraception methods that do not result in a failure rate of <1% per year such as cap, diaphragm, or sponge with spermicide, or male or female condom with or without spermicide, are not acceptable. 4. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. 4. For men: agreement to remain abstinent or use contraceptive measures and agreement to refrain from donating sperm, as defined below: a) With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of <1% per year during the treatment period and for at least 120 days (a spermatogenesis cycle) after the last dose of study intervention. Men must refrain from donating sperm during this same time period. 5. Able to undergo two PET/CT scans as part of the study, including ability to lie supine for up to 1 hour. 6. Has a history of AL or ATTR systemic amyloidosis with at least one organ with clinically demonstrable amyloid involvement defined by: 1. AL systemic amyloidosis: Positive tissue biopsy for AL amyloid, and achieved a hematologic very good partial response or complete response based on their most recent assessment, and at least one of the following: 1) Organ biopsy positive for amyloid, or 2) Natriuretic peptide (NT-proBNP) >650 pg/mL, or 3) left ventricle septal wall thickness >12 mm by echocardiogram or cardiac magnetic resonance (CMR), or 4) 24-hour urine protein >500 mg, or 5) Urine albumin-to-creatinine ratio >300 mg/g 2. ATTR (wild type or variant) systemic amyloidosis: Positive cardiac biopsy for ATTR amyloid, or at least two of the following: 1) Positive extracardiac tissue biopsy for ATTR amyloid or positive transthyretin gene mutation associated with amyloid, or 2) left ventricle septal wall thickness >12 mm by echocardiogram or CMR, or 3) pyrophosphate (PYP) scintigraphy with myocardial uptake =grade 2. Exclusion Criteria 1. Is pregnant or breast-feeding. 2. Is mentally or legally incapacitated, has significant emotional problems at the time of the study, or has a history of psychosis. 3. Has received in the last 6 months or are currently receiving treatment with anti-amyloid monoclonal antibody therapy or are expected to begin treatment prior to completing this study. 4. Has received heparin or heparin analogs within 7 days of Day 1. 5. Has a significant co-morbidity (e.g., Easter Cooperative Oncology Group (ECOG) score of 3 or greater), New York Heart Association (NYHA) Class IV heart failure, uncontrolled infection, or other ongoing serious illness. 6. Has active thyroid disease. 7. Has a known allergy to potassium iodine treatment. 8. Is receiving hemodialysis or peritoneal dialysis. 9. Has severe claustrophobia that would prevent completion of the PET/CT imaging protocol. 10. Has received an investigational agent within five half-lives of the agent or 30 days, whichever is longer, prior to Screening. 11. Has any illness that, in the opinion of the Investigator, might confound the results of the study or pose additional risk to the subject.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
I124-AT01 only
Intravenous injection of I124-AT01 on Day 1 and again at Week 6 followed by a full body Positron Emission Tomography/Computed Tomography (PET/CT) scan.

Locations

Country Name City State
United States PET/CT Imaging of Berkeley Berkeley California
United States Northern California PET Imaging Center Sacramento California
United States PET/CT Imaging of San Jose San Jose California

Sponsors (1)

Lead Sponsor Collaborator
Attralus, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Repeatability of organ specific quantitation of radiotracer uptake at baseline and 6 weeks. To evaluate the repeatability of organ-specific quantitation of radiotracer uptake following PET/CT imaging of 124I-AT-01 in subjects with AL or ATTR systemic amyloidosis at baseline and the repeated scan at 6 weeks. Repeatability coefficient (Bland-Altman plots) associated with the quantification of radioactivity associated with organ level 124I-AT-01 uptake measurements at 6 weeks..
Primary Repeatability of organ specific quantitation of radiotracer uptake at baseline and 6 weeks. To evaluate the repeatability of organ-specific quantitation of radiotracer uptake following PET/CT imaging of 124I-AT-01 in subjects with AL or ATTR systemic amyloidosis at baseline and the repeated scan at 6 weeks. intraclass correlation coefficient (ICC) associated with the quantification of radioactivity associated with organ level 124I-AT-01 uptake measurements at 6 weeks..
Secondary Incidence of treatment-emergent adverse events [safety and tolerability] To characterize the safety and tolerability of repeat doses of 124I-AT-01 administered by IV infusion at 6 weeks (Visit 2) and the safety follow-up visits at 24-48 hours after the second infusion and 28 days after the second infusion. Incidence of treatment-emergent adverse events (AEs) from Day 1 to End of Study (EOS), up to 14 weeks.
Secondary Number of participants with abnormal hematology and chemistry laboratory test results. Change from Baseline in hematology and chemistry laboratory values at Visits 2 and Safety Follow-up 1 (24-48 hours after the second infusion). At visit 2 (week 6) and Safety Follow-Up 1 at 24-48 hours after the second infusion (up to 48 hours after the week 6 visit)..
Secondary Number of participants with abnormal vital signs. Any abnormal change from Baseline in blood pressure and pulse measurements at visit 2 (week 6) and at the safety follow-up visit 24-48 hours after the week 6 visit and again at 28 days after the week 6 visit. Change from Baseline in vital signs at visit 2 (week 6) and safety follow-ups at 24-48 hours after the second infusion (week 6) and 28 days after the second infusion at the week 6 visit..
Secondary Change from Baseline in anti-drug antibody (ADA). Change from Baseline in anti-drug antibody (ADA). Visit 2 (week 6) and safety follow-up 2 at 28 days following the second infusion at week 6.
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Withdrawn NCT04943302 - Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis Phase 2
Active, not recruiting NCT02909036 - Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. Phase 1
Completed NCT02816476 - Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis Phase 2
Completed NCT01083316 - Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis Phase 2
Completed NCT01527032 - Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis Phase 2
Completed NCT02545907 - A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis Phase 1/Phase 2
Recruiting NCT05263817 - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis Early Phase 1
Active, not recruiting NCT03201965 - A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Phase 3
Withdrawn NCT02589860 - Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02574676 - Quality of Life (QOL) Registry for Patients With AL Amyloidosis
Active, not recruiting NCT02260466 - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. N/A
Withdrawn NCT02462213 - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging N/A
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Completed NCT01406314 - SAP Depleter Dose Assessment Study in Patients Phase 1
Not yet recruiting NCT04985734 - Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy N/A
Active, not recruiting NCT03584022 - Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial N/A
Active, not recruiting NCT05199337 - Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis Phase 1/Phase 2
Completed NCT02716103 - Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis